Scholarlink

<p>This study presents a novel approach to embolization by developing biocompatible blood clot particles using natural substances and FDA-approved materials to address the limitations of currently used embolic agents, such as microspheres, gel foam, and polyvinyl alcohol, which are associated with immune responses and bleeding. By utilizing blood clot particles, the study aimed to reduce these side effects while maintaining effective embolization. The process involved injecting tissue plasminogen activator and plasmin to degrade the blood clot particles at a desired time, ensuring control over the embolization duration. To evaluate the particles, a 3D microfluidic chip was designed to simulate blood vessels, and the embolization effect was tested along with the potential inflammatory response. Human Umbilical Vein Endothelial Cells were cultured on the chip to assess inflammation by tracking tumor necrosis factor-α and interleukin-6 levels during embolization. Key findings of the study showed that these biocompatible blood clot particles successfully achieved embolization for about 7&#xa0;days and triggered a lower release of inflammatory cytokines compared to standard microspheres. This suggests that blood clot particles could serve as a viable alternative for embolization, offering improved biocompatibility and a manageable embolization duration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered Blood Clots for Embolization in a 3D Microfluidic Chip Model Mimicking Vascular Structures

  • 期刊论文

  • 发表日期：

    2025年5月20日

查看全文
  • Jiwon Kim,
  • Jihyuk Yang,
  • Suyeon Ahn,
  • Yonghyun Choi,
  • Masayoshi Tanaka,
  • Jaehee Jang,
  • Yeongseon Cho,
  • Hong Nam Kim,
  • Hee-Young Lee,
  • Jonghoon Choi

摘要

This study presents a novel approach to embolization by developing biocompatible blood clot particles using natural substances and FDA-approved materials to address the limitations of currently used embolic agents, such as microspheres, gel foam, and polyvinyl alcohol, which are associated with immune responses and bleeding. By utilizing blood clot particles, the study aimed to reduce these side effects while maintaining effective embolization. The process involved injecting tissue plasminogen activator and plasmin to degrade the blood clot particles at a desired time, ensuring control over the embolization duration. To evaluate the particles, a 3D microfluidic chip was designed to simulate blood vessels, and the embolization effect was tested along with the potential inflammatory response. Human Umbilical Vein Endothelial Cells were cultured on the chip to assess inflammation by tracking tumor necrosis factor-α and interleukin-6 levels during embolization. Key findings of the study showed that these biocompatible blood clot particles successfully achieved embolization for about 7 days and triggered a lower release of inflammatory cytokines compared to standard microspheres. This suggests that blood clot particles could serve as a viable alternative for embolization, offering improved biocompatibility and a manageable embolization duration.